Rapid Response Service review for TOBI^TM initiated by Newfoundland’s Pharmaceutical Services Division
 

The Atlantic Common Drug Review (ACDR) committee reviewed TOBI^TM on two occasions, in 2007 and 2011. Both resulted in recommendations that TOBI^TM should not be reimbursed by public drug plans in the Atlantic provinces. 

The Newfoundland Pharmaceutical Services Division have made a request to the Canadian Agency for Drugs and Technologies in Health (CADTH) to complete a Rapid Response Service review with respect to the comparative evidence for TOBI^TM and inhaled tobramycin. This is being undertaken to provide a second independent assessment which could impact the ACDR’s negative recommendation regarding reimbursement of TOBI^TM.

Although there is not yet a precise timeframe for the completion of this review, Cystic Fibrosis Canada will monitor progress closely and keep you informed.

Reviewed/updated: 2012-12-11